{"id":687598,"date":"2022-09-21T09:46:29","date_gmt":"2022-09-21T13:46:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"modified":"2022-09-21T09:46:29","modified_gmt":"2022-09-21T13:46:29","slug":"cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","title":{"rendered":"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BERKELEY HEIGHTS, N.J., Sept.  21, 2022  (GLOBE NEWSWIRE) &#8212; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann\u2019s 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Event:<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Ladenburg Thalmann 2022 Healthcare Conference<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Date:<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Thursday, September 29, 2022<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Time\/location:<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">9:30am ET, Track 2, St Germain III<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Format:<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Fireside Chat Presentation<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Webcast:<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"https:\/\/wsw.com\/webcast\/ladenburg8\/register.aspx?conf=ladenburg8&amp;page=cycc&amp;url=https:\/\/wsw.com\/webcast\/ladenburg8\/cycc\/2394776\" rel=\"nofollow noopener\" target=\"_blank\">Link<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"left\">\n        <strong>About Cyclacel Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p align=\"left\">Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2\/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies.\u00a0Cyclacel&#8217;s\u00a0strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_J18ergIi7cDE2W6gk-qxVHKH6jWD-VIw1uKirqdUn_GN4hxfQZaau0V2V2SEE_JAPZyTipSjvkDY97uZfL53Q==\" rel=\"nofollow noopener\" target=\"_blank\">www.cyclacel.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Contacts<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">Company:<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">Paul McBarron, (908) 517-7330,\u00a0<a href=\"mailto:pmcbarron@cyclacel.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>pmcbarron@cyclacel.com<\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">Investor Relations:<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">Irina Koffler, LifeSci Advisors, LLC,\u00a0(646) 970-4681,\u00a0<a href=\"mailto:ikoffler@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">ikoffler@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p align=\"left\">\u00a9 Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel<sup>\u00ae<\/sup> are trademarks of Cyclacel Pharmaceuticals, Inc.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTkwODA1MDAtNTAyMS00ZmU5LTk1MDQtMzMyZGI5Mjc2NWZiLTEwMTgzMTQ=\/tiny\/Cyclacel.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann\u2019s 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York. Event: Ladenburg Thalmann 2022 Healthcare Conference Date: Thursday, September 29, 2022 Time\/location: 9:30am ET, Track 2, St Germain III Format: Fireside Chat Presentation Webcast: Link About Cyclacel Pharmaceuticals, Inc. Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2\/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687598","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann\u2019s 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York. Event: Ladenburg Thalmann 2022 Healthcare Conference Date: Thursday, September 29, 2022 Time\/location: 9:30am ET, Track 2, St Germain III Format: Fireside Chat Presentation Webcast: Link About Cyclacel Pharmaceuticals, Inc. Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2\/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with &hellip; Continue reading &quot;Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T13:46:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference\",\"datePublished\":\"2022-09-21T13:46:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"},\"wordCount\":198,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\",\"name\":\"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=\",\"datePublished\":\"2022-09-21T13:46:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","og_description":"BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann\u2019s 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York. Event: Ladenburg Thalmann 2022 Healthcare Conference Date: Thursday, September 29, 2022 Time\/location: 9:30am ET, Track 2, St Germain III Format: Fireside Chat Presentation Webcast: Link About Cyclacel Pharmaceuticals, Inc. Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2\/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with &hellip; Continue reading \"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-21T13:46:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference","datePublished":"2022-09-21T13:46:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"wordCount":198,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","name":"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=","datePublished":"2022-09-21T13:46:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDMwMyM1MTYzMDIxIzIwMDY3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687598"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687598\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}